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Abstract 
Life-threatening herpes simplex virus encephalitis (HSE) is the most common form of sporadic 
viral encephalitis worldwide. A diverse collection of genetic etiologies can predispose to this 
condition: inborn errors of the TLR3 responsive pathway impair central nervous system (CNS) 
cortical neuron- and oligodendrocyte-intrinsic immunity to herpes simplex virus type 1 (HSV-1) 
and underlie forebrain HSE; heterozygous SNORA31 variants have also been associated with 
forebrain HSE; last, genetic defects of RNA lariat metabolism, due to mutations in DBR1, can 
trigger brainstem HSE. Still, the vast majority of HSE patients enrolled in our cohort lack a genetic 
diagnose. Here, we report autosomal recessive RIPK3 deficiency in a patient with recurrent 
forebrain HSE. The patient is compound heterozygous for one nonsense and one frameshift 
RIPK3 mutations that lead to impaired protein expression and function of RIPK3 via distinct 
mechanisms. We show that the patient’s fibroblasts do not phosphorylate MLKL upon stimulation 
via TNFR1 or TLR3, while the production of IFN-b or -l was normal upon TLR3 activation. We 
further demonstrate that the TLR3-induced RIPK3-dependent necroptosis signaling cascade is 
selectively impaired in fibroblasts from previously described patients with TLR3 pathway 
deficiencies. Taken together, our findings suggest that RIPK3 deficiency predisposes to HSE, due 
to disruption of the TLR3-RIPK3-mediated necroptosis pathway. This novel genetic etiology 
expands our understanding of the TLR3 circuit as a non-redundant mechanism of antiviral 
immunity of the CNS in humans. 
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Abstract en español 
La encefalitis herpética (HSE) es la forma más común de encefalitis esporádica en todo el mundo. 
La predisposición a esta condición está causada por un grupo heterogéneo de etiologías 
genéticas: Mutaciones en la vía del TLR3 dañan a la inmunidad intrínseca de las neuronas y los 
oligodendrocitos del Sistema Nervioso Central (SNC) frente al virus del herpes simple tipo 1 
(VHS-1) y son responsables de ciertos casos de encefalitis herpética en el lóbulo frontal. Del 
mismo modo, mutaciones heterocigóticas en SNORA31 también ha sido asociadas con la 
encefalitis herpética frontal; por último, defectos genéticos del metabolismo de los lazos de ARN, 
causados por mutaciones en DBR1, pueden causar encefalitis herpética en el tallo cerebral. Sin 
embargo, la mayor parte de los pacientes de nuestra cohorte de pacientes con encefalitis 
herpética no tiene una etiología genética identificada. Aquí describimos un paciente con 
encefalitis herpética con deficiencia en RIPK3 autosómica recesiva. El paciente es heterocigoto 
compuesto por una mutación nonsense y una mutación frameshift que conducen a la pérdida de 
expresión y función de la proteína mediante distintos mecanismos. Nuestros resultados muestran 
que los fibroblastos del paciente no fosforilan MLKL tras la estimulación de la vía del TLR3 y la 
del TNFR1. Sin embargo, la producción de interferones b y l es normal tras la activación del 
TLR3. También demostramos que la vía inducida por el TLR3 y mediada por RIPK3 está 
selectivamente dañada en fibroblastos de pacientes previamente descritos con mutaciones en la 
ruta del TLR3. Esto sugiere que deficiencia en RIPK3 predispone a la encefalitis herpética y que 
lo hace de forma dependiente del TLR3. Esta nueva etiología genética expande nuestro 
conocimiento sobre el papel del circuito gobernado por el TLR3 como un mecanismo no 
redundante en la inmunidad antiviral del SNC en humanos. 
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1.1 Herpes Simplex Viruses 
 
Herpesviruses are a large family of double-stranded DNA viruses that can infect a broad spectrum 
of species of a minimum of two animal phyla, the Chordata (mammals, birds, fishes, reptiles, and 
amphibians) and also the Mollusca (oysters) (Pellet and Roizman 2007). Additionally, these 
viruses can enter and replicate in a wide selection of cell types within the same host, suggesting 
that, throughout evolution, these viruses have developed effective tactics to enter and manipulate 
different spaces where they can replicate. The family Herpesviridae is split into three subfamilies 
(Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae) based on their biological 
properties and genome sequences (Davison et al. 2009). The Alphaherpesvirinae subfamily 
contains five documented genera containing a total of 37 distinctive species, of which three virus 
species typically infect humans: herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and 
varicella-zoster virus (VZV).  
 
One characteristic of human herpesviruses is that, following primary infection, the viruses can 
remain silent in cells they populate. At intervals, they can reactivate and transport to a portal of 
egress from the body where they will disseminate to other individuals. This property has made 
HSV-1 and HSV-2 great model systems for the study of the latent infection (Whitley et al., 2009). 
These observations were initially made at the beginning of the 20th century, when Cushing 
(Cushing et al. 1905) realized that, following the sectioning of the connection between trigeminal 
ganglion (TG) and the brain, typical herpetic lesions appeared along the sites innervated by the 
TG. These studies were meticulously documented patient by patient and led to the irrefutable 
conclusion that the reactivation originated from sensory ganglia. The connection between primary 
infection and reactivation was nevertheless controversial until Burnet and Williams (Burnet and 
Williams, 1939) proposed that, following primary infection, the virus enters into a latent state, 
occasionally reactivating and causing recurrent lesions. We currently know that HSVs codify a 
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minimum of 84 proteins and several long noncoding RNAs and micro RNAs in infected cells 
(Roizman et al., 2006). The virus is transported retrogradely to sensory or autonomic neurons 
(peripheral ganglia innervating that site). Once it establishes latency in peripheral ganglia, the 
viral DNA is maintained within the cells as an episome; the virus expresses a prominent noncoding 
intron called latency-associated transcript (LAT), a group of RNAs and a group of miRNAs (Fuller 
et al., 1989; Gross et al., 2003; Hill et al., 1972; Hill et al., 1973). When the virus reactivates, it 
replicates within the neuron and then travels through anterograde transport to a portal of entry 
into the body. 
 
Exposure of the mucosal surfaces of a seronegative individual to infected secretions from a 
seropositive individual may end in primary infection. Seeding of innervating ganglia follows, and 
new latency is established as a consequence of this sequence of events. Depending on many 
factors, the virus might reactivate with the appearance of symptomatic lesions.  
 
The transmission of HSVs is very common, as measured by the seroprevalence of HSV-1 and 
HSV-2 (Feierbach et al., 2007). In developed countries, around 20% of teenagers to 60-80% of 
adults by the age of fifty are infected with HSV-1. In contrast, in developing countries, HSV-1 is 
acquired much earlier in life, approaching 50% by early adulthood and 90% by midlife.  
 
Our knowledge of HSV-2 infections, in many respects, is significantly more advanced than it is for 
HSV-1 due to its propensity for sexual transmission with psychosocial implications, attendant 
morbidity, and mortality in the infected newborn, and the higher risk of acquisition of HIV infection 
by infected individuals (Hook et al.,2006; Mark et al., 2008).  
Globally, the acquisition of HSV-2 begins with the onset of sexual intercourse, and like HSV-1, it 
occurs earlier in life within the developing world than in developed societies. From the mid-1990s 
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to 2005, the seroprevalence of HSV-2 declined from about 24% to 19% (Fleming et al., 1997; Xu 
et al., 2006). Still, seroprevalence rises overall to near 30% by midlife, varying to some extent 
from nation to nation. It is worth mentioning that these data do not account for HSV-1 infections 
of the genital tract due to our lack of serologic or biologic markers to define their contribution to 
genital infections. The infection burden is high worldwide; however, most infected individuals are 
unaware that they are infected, and plenty experience asymptomatic recurrences and shed the 
virus.  
Although the prevalence of HSV infections is very high, most infected individuals are either 
asymptomatic or develop mild symptoms. However, these infections can lead to life-threatening 
conditions in some patients. Therefore, a deep understanding of the interactions between herpes 
simplex viruses and humans is necessary to prevent and treat those cases. 
 
1.2 Clinical manifestations of Herpes Simplex virus in humans 
HSVs have coevolved with the species they infect for millions of years: HSV-1 for around 6 million 
years and HSV-2 for 1.6 million years approximately. Humans and HSVs have developed a 
prosperous equilibrium, where the viruses can establish latency and remain inside its host for the 
rest of its lifespan. This balance between humans and virus involves host recognition of the virus 
infection and efforts to clear it, while the virus changes to escape the host immune responses. 
Through this evolutionary chess game, the HSVs and the human host have developed a durable 
coexistence. However, disease may result if the viral load is too high or if the host fails to provide 
a proper immune response. 
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1.2.1 Herpes labialis 
Herpes labialis, also known as cold sores, is a type of infection that affects the lips primarily 
(Opstelten et al., 2008). Patients with herpes labialis usually suffer from burning pain within the 
infected area, followed by small blisters or sores. The primary infection may include fever, 
pharyngitis, and inflammation of the lymph nodes (Stoopler et al., 2014). Testing is rare, and 
diagnosis usually relies on symptoms.  The rash usually lasts around ten days, but the virus 
remains dormant in the trigeminal ganglion. The virus can reactivate periodically and create new 
sores in the mouth or the lips. HSV-1 causes the vast majority of the cases of oral herpes. 
However, cold sores caused by HSV-2 have also been reported (Opstelten et al., 2008). The 
infection is transmitted among individuals by non-sexual physical contact. Several agents can 
trigger the activation of the latent virus, including sunlight exposure, fever, mental stress, or 
menstruation. Physical contact with the genitalia can result in genital herpes. 
Prevention includes avoiding kissing or using personal items of an infected person. A zinc oxide, 
anesthetic, or antiviral creams can decrease the duration of symptoms and the frequency of 
outbreaks (Rahimi et al., 2012). About 0.2% of the population suffers from herpes labialis 
outbreaks in any given year. After the first episode, one-third of people develop subsequent 
outbreaks. Onset occurs in children and young adults, but most of the affected individuals produce 
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1.2.2 Herpes gingivostomatitis 
Herpes gingivostomatitis (HGS) is an inflammation of the oral mucosa and gingiva caused by a 
herpes simplex infection (Kolokotronis et al., 2006). It is of greater severity than herpes labialis, 
which is often how the infection presents in individuals presenting with this condition. Similar to 
herpes labialis, HGS is induced predominantly by HSV-1 and affects mainly children and young 
adults. The disease manifests as copious vesicles, which rupture speedily to make uncomfortable 
ulcerations screened by yellow-grey membranes. Well-known symptoms observed in these 
include sub-mandibular lymphadenitis, halitosis, and refusal to drink. (Kolokotronis et al., 2006). 
 
 
1.2.3 Herpes genitalis 
Herpes genitalis is an infection of the genitals caused by herpes simplex viruses (Gupta et al., 
2007). Most infected individuals do not present any symptoms and therefore are not aware of the 
infection. (Gupta et al., 2007). The most common symptom of this condition is the appearance of 
blisters, which occasionally lead to the formation of painful ulcers. Other symptoms like aching, 
fever or swollen lymph nodes are observed in a smaller fraction of patients. Onset occurs around 
four days after infection, and symptoms can last for a month. Once infected, further outbreaks 
can happen, but they are generally milder. 
Herpes genitalis is a sexually transmitted disease typically spread by direct contact with the skin 
surface or secretions of someone infected. HSV-2  is commonly believed to be the most common 
and almost only cause of herpes genitalis. However, in the past decade, the USA, Canada, and 
several European countries have seen an increase in genital HSV-1 infections, which now 
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account for at least half of the first episodes of the cases. (Roberts et al., 2003; Scoular et al., 
2002; Manavi et al., 2004; Coyle et al., 2003). This increase may result from a delay in the 
acquisition of oral HSV-1 infection early in life in developing countries, therefore remaining 
susceptible to genital HSV-1 infection at the initiation of sexual activity (Xu et al., 2006). HSV-2 
infection has also been linked to a higher risk of sexually acquired HIV (Freeman et al., 2006). 
The mucosal disruption caused by genital ulcers facilitates HIV acquisition by providing an 
immediate gate (Corey et al., 2004). Besides, HSV-2 reactivation results in mucosal infiltration 
with activated CD4-bearing lymphocytes, which HIV-1 targets for attachment (Koelle, 1994). 
 
 
1.2.4 Herpes gladiatorum 
Herpes gladiatorum, also referred to as herpes rugbiorum, “mat herpes” or “wrestler herpes” due 
to its association with contact sports, is an infection of the skin that can affect the head, 
extremities, and trunk (Likness et al., 2011). Symptoms include rash with blisters on the neck, 
chest, face, stomach, and legs;  and less often, lymphadenopathy, fever, sore throat, and 
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1.2.5 Herpes esophagitis 
Herpes esophagitis is an infection of the esophagus caused by HSVs. The disease is most 
frequent in immunocompromised patients (Mcbane et al., 1991), but immunocompetent 
individuals have nonetheless been reported (Kato et al., 2005). Symptoms include pain with 
eating trouble swallowing and, on rare occasions, upper gastrointestinal bleeding (Takeno et al., 
2002). Herpes esophagitis is usually diagnosed by inference based on symptoms. However, the 
obtention of biopsies through endoscopy can is more accurate. Pathologists may find inclusion 
bodies by microscopy and immunochemical staining (Bennett et al., 2009). Treatment consists of 
antiviral drugs such as valacyclovir or acyclovir. Patients who cannot swallow because of the pain, 
individuals with other systemic manifestations of herpes, and severely immunocompromised 
individuals are treated with intravenous acyclovir.  
 
1.2.6 Herpes whitlow 
A herpetic whitlow is an unpleasant infection on a finger or thumb caused by HSVs. In some 
instances, disease happens on the nail cuticle or the toes (Clark, D, 2003). Healthcare workers 
represent a sizable fraction of infected individuals as they come in contact with the virus, primarily 
dental workers and medical workers exposed to oral secretions (Avitzur et al., 2002; Lewis et al., 
2004). It is also observed in children with HSV-1 oral infection with a tendency to suck their thumbs 
before seroconversion (autoinoculation) (Clark, D, 2003) and in young adults following contact 
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1.2.7 Herpes keratinitis 
Herpes keratinitis is a type of inflammation caused by HSV infection of the cornea. HSV infects 
the epithelial cells around the eye, and retrograde transport of the virus allows it to reach the 
cornea (Carr et al., 2001). Primary infection typically presents as puffiness of the conjunctiva and 
eyelids, accompanied by tiny white itchy lesions on the corneal surface. The severity of the lesions 
ranges from minor disruption of the epithelium to more severe consequences like the formation 
of dendritic ulcers (Kaye et al.,2006). Other symptoms include pain inside the eye, dryness, and 
sinusitis, occurring in only one eye in most cases. These primary infections usually resolve 
spontaneously in a couple of weeks. Oral and topical antivirals can boost healing.  
Recurrent infections can be more severe, with infected epithelial cells showing larger dendritic 
ulceration, and lesions forming white plaques. (Kaye et al.,2006). Mild inflammation may occur in 
the underlying stroma of the iris. Eye dryness and conjunctivitis may also occur. Persistent 
infection can trigger a massive immune response in the eye which can potentially lead to the 
destruction of the corneal stroma, resulting in loss of vision (Faaroq et al., 2012).  
 
1.2.8 Herpes simplex encephalitis 
1.2.8.1 Pathology 
Herpes simplex encephalitis (HSE; OMIM ID 613002) is a virus infection-triggered high 
inflammation of the central nervous system (Gnann et al., 2017). The mechanism by which the 
virus reactivates and reaches the CNS is not fully understood. Reactivation of HSV has been 
proposed to occur in peripheral ganglia with axonal transport to the temporal lobe or directly in 
the brain. Four main routes of infection have been suggested: 
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1) Primary infection of the oropharynx with CNS invasion via the trigeminal or olfactory tracts, 
which is the most widely accepted (Jennische et al., 2015; Menasria et al., 2015).  
2) Primary infection with CNS infection resulting from hematogenous spread. 
3) CNS invasion after an episode of recurrent orofacial HSV-1 infection, representing 
peripheral viral reactivation with the subsequent axonal spread. (Whitley et al., 1982) 
4) CNS infection without defined peripheral HSV-1 infection, possibly representing the 
reactivation of latent virus within the CNS (Baringer et al., 1994). 
HSE is characterized by necrotizing encephalitis involving -in most cases- the temporal lobe, the 
frontal lobe, and/or the insular cortex of the cerebral hemispheres (Taylor et al., 2005). Necrosis 
occurs in all cell types, including neurons, astrocytes, and oligodendrocytes. This life-threatening 
condition usually starts with infection in only one temporal lobe. Still, bilateral involvement is often 
seen in autopsy studies, indicating that the increase in viral load eventually leads to the invasion 
of the contralateral hemisphere. CNS pathology in these patients is produced by a combination 
of cytolytic viral replication and immune-mediated mechanisms. Type I interferons are required 
for survival in mice models of HSE (Wang et al., 2012). In addition, patients with HSE show 
detectable levels of cytokines and soluble cytokine receptors (including IL- 6, interferon-gamma, 
TNF-alpha, IL-2 receptor, and soluble CD8 antigen) in serum and CSF at various stages of the 
illness. The existence of these inflammatory markers indicates that during acute HSV, the robust 





Thesis dissertation of Eduardo J. Garcia Reino 
Bi-allelic RIPK3 mutations in a patient with Herpes Simplex Encephalitis 
20 
1.2.8.2 Clinical manifestations 
Patients typically present with fever, headache, focal neurologic findings (including cranial nerve 
deficits, hemiparesis, dysphasia, aphasia, or ataxia), altered mentation, and reduced level of 
consciousness of short duration (less than one week). Behavioral changes (especially in adults: 
elevated mood, excessive animation, decreased need for sleep, inflated self-esteem, and 
hypersexuality, and Kluver-Bucy syndrome) and occasional hallucinations have also been 
reported. (Riera-Mestre., 2009; Domingues et al., 1997). Seizures are also observed in about 
one-half of cases (Singh et al., 2016). Interestingly, HSE is not accompanied by the dissemination 
of the virus to other organs, and patients with HSE are not particularly susceptible to other HSV-
1 diseases of the skin or mucosa.  
1.2.8.3 Epidemiology 
Herpes simplex virus type 1 (HSV-1) encephalitis (HSE) is the most common cause of sporadic 
viral encephalitis in Western countries, occurring at a rate of 1-2 per 500,000 individuals per year 
(Hjalmarsson et al., 2007; Kohl et al., 1998; Mailles et al., 2007; Whitley et al., 2002). HSE occurs 
worldwide and has no seasonal variation; prevalence among males and females is the same. 
HSE can affect patients at almost any age, but there are 2 peaks of incidence, the first at age 6 
months to 3 years, corresponding mainly to primary infection, and the second at age >50 years, 
probably reflecting viral reactivation (De Tiege et al., 2003 Whitley et al., 2005; Abel et al., 2010). 
About one-third of HSE cases are related to primary HSV infection (more commonly in children 
and adolescents), while the remaining are attributed to HSV reactivation. Clinical features do not 
help to discriminate between HSE caused by one or the other. The introduction of acyclovir 
treatment has considerably reduced HSE mortality, although neurologic sequelae are common, 
especially in young children (Hjalmarsson et al., 2007; McGrath et al., 1997, Raschilas et al., 
2002). Studies evaluating the clinical outcome of children with HSE treated with acyclovir have 
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shown that although the overall mortality rate was low, a substantial proportion (35%-62%) had 
significant neurological sequelae (Elbers et al., 2007; Hsich et al., 2007). 
 
1.2.8.4 Diagnosis 
A lumbar puncture (LP) must be performed in all individuals with suspected HSE unless there is 
a contraindication (e.g., elevated intracranial pressure). Standard cerebrospinal fluid (CSF) 
abnormalities include increased protein (50–200 mg/ dL or more; median about 80 mg/dL), CSF 
leukocytosis (5– 500 cells/mm3 or more, median about 70 cells/mm3) with predominance of 
lymphocytes (60–98%, median about 80%). CSF pleocytosis with >5 WBC/mm3 is observed in 
the vast majority of the cases, although HSE cases without CSF leukocytes have been described 
(Lopez Roa et al., 2013; Rawal et al., 2015; Razavi et al., 2001). However, the absence of CSF 
leukocytes should not eliminate HSE from diagnostic consideration when the clinical phenotype 
is otherwise indicative of this being the case. Red blood cells in CSF occurs more often in HSE 
patients with substantial tissue necrosis. Glucose values are usually average, although cases of 
hypoglycorrhachia have been described (Davis et al., 2004). The demonstration of HSV DNA in 
CSF using a polymerase chain reaction (PCR) assay is the most reliable evidence for HSE 
(Aurelius et al., 1991; Lakeman et al., 1995; Steiner et al., 2010). In HSE caused by HSV-1, the 
sensitivity of PCR is estimated to be 98% with specificity 94– 99%. The SimplexaTM HSV-1 and 
2 Direct kit (Focus Diagnostics) is FDA-approved for the detection of HSV DNA in CSF (Binnicker 
et al., 2014).  
PCR is generally positive after 24 hours of symptom onset and remains positive during the first 
week of acyclovir therapy. Negative CSF PCR has been reported in HSE patients who were tested 
very early in their clinical course (Adler et al., 2011; Weil et al., 2002). In those cases, if the clinical 
manifestations strongly suggest that it is HSE, acyclovir therapy should not be discontinued, and 
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the patient should undergo a second lumbar puncture;  when the patient is retested the PCR 
normally comes positive. False-negative PCR results may also occur as a result of a suboptimal 
assay or due to the presence of inhibitory substances in CSF, such as blood. False-positive 
results are rare but occasionally occur (as with any PCR-based assay), probably because of 
cross-contamination. Due to its high efficacy, the PCR has substituted brain biopsies. However,  
brain biopsy may still be required in exceptional cases when the clinical and radiographic 
evidence indicate HSE, but the PCR is nondiagnostic. HSV can be identified in brain tissue by 
PCR, viral culture, in situ hybridization, or immunohistochemical staining. Assays for the detection 
of HSV antigens and anti-HSV antibodies in CSF have been described but have been replaced 
by PCR. These tests can be helpful as an alternative to brain biopsy in those cases where HSE 
is heavily suspected, but the PCR is repeatedly negative (Bhullar et al., 2016; Denes et al., 2010).  
Magnetic resonance imaging (MRI) is the preferred imaging technique for patients with this 
condition (McCabe et al., 2003; Mekan et al., 2005). However, antiviral therapy should be initiated 
as soon as possible, while imaging studies are performed. After a median duration of neurologic 
symptoms of 3 days, 95% of patients had an abnormal MRI, although scans performed very early 
in the course of the disease may occasionally be normal (Tyler et al., 2004). The MRI typically 
shows abnormalities in the temporal lobe or neighboring areas early in the course of infection and 
can normally distinguish HSE from a cerebrovascular injury, tumor, or brain abscess. HSE usually 
affects only one lobe, but can be bihemispheric, especially later on in the course of the disease. 
Compared with MRI, computed tomography (CT) scanning is less sensitive for detecting the early 
stages of HSE. However, CT may be useful in the emergency department for assessing mass 
effect and excluding other possible diagnoses (e.g., intracranial hemorrhage) (Stahl et al., 2012). 
The MRI pattern of HSV-2 encephalitis is more heterogeneous than HSV-1 encephalitis (Singh et 
al., 2016). Dynamic single-photon emission computed tomography (SPECT) scanning may have 
utility in the diagnosis of HSE, but experience is currently limited (Kataoka et al., 2007). 
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1.2.8.5 Treatment 
Medical management of HSE includes intensive supportive care, seizure control (if necessary), 
and early initiation of antiviral therapy with intravenous acyclovir (Sellner et al., 2012; Tunkel et 
al., 2008). Early diagnosis is essential, but clinicians should not wait for confirmatory laboratory 
testing before starting intravenous acyclovir therapy in patients with clinically suspected HSE 
(Steiner et al., 2010; Hughes et al., 2012). Neurological intervention has been beneficial in some 
patients with life-threatening increases in intracranial pressure (Jouan et al., 2015; Maraite et al., 
2010). Following the completion of antiviral treatment, survivors will often benefit from physical 
therapy and occupational therapy.  
 
The efficacy of acyclovir for the treatment of HSE was proven in a series of randomized, controlled 
clinical trials conducted in the 1980s that demonstrated a reduction in mortality from about 70% 
(without antiviral therapy) to about 25% (Skoldenberg et al., 1984; Whitley et al., 1986).  Acyclovir 
is the only antiviral drug that is FDA-approved for the treatment of HSE. In early clinical trials, 
acyclovir was studied at doses of 10 mg/kg administered every 8 hours (30 mg/kg/ day) for 10 
days. However, due to suboptimal outcomes even in patients receiving appropriate acyclovir 
therapy, many experts recommend the administration of higher doses (36–45 mg/kg/day) for 
longer durations (14–21 days), even though these conditions have not been rigorously examined 
in controlled clinical trials. These recommendations are based on the observation that neonates 
with persistently positive CSF for HSV after 10 days of acyclovir therapy had higher rates of 
morbidity and mortality (Kimberlin et al., 1996). If the PCR is negative, but the clinical 
manifestations strongly suggest HSE (compatible MRI findings, CSF pleocytosis >5 cells/mm3, 
abnormal EEG, or seizures), acyclovir therapy should not be discontinued.  
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In theory, corticosteroids could suppress the inflammatory responses in the CNS during HSE and 
reduce immune-mediated pathology. In a mouse model of HSE, combination therapy with 
acyclovir plus glucocorticosteroids significantly reduced the frequency of long-term MRI 
abnormalities (Meyding-Lamade et al., 2003). The main concern is that immunosuppressive 
corticosteroid therapy could enhance viral replication and increase the risk of dissemination; 
however, no increase in intracranial viral load or extent of brain involvement has been seen in 
animal models (Thompson et al., 2000; Meyding-Lamade et al., 2003). Evidence is not yet 
sufficient to endorse the use of concomitant therapy with corticosteroids in HSE as a standard 
practice (Ramos-Estebanez et al., 2008). 
1.2.8.6 Post infection complications 
Herpes simplex encephalitis, and possibly other viral encephalitides, can trigger antibodies 
against the NMDAR and other neuronal cell-surface proteins; such antibodies are responsible for 
the relapsing neurologic symptoms that arise weeks after the onset of HSE. (Armangue et al., 
2015; Linnoila et al., 2016) This delayed complication affects approximately 20% of patients with 
HSE and is manifested predominantly as choreoathetosis in children and as psychiatric and 
behavioral alterations in adults (Armangue et al., 2015; Hacohen et al., 2014) Immunotherapy 
with glucocorticoids, plasma exchange, intravenous immune globulin, or rituximab is somewhat 
effective during relapse and does not appear to confer a predisposition to reactivation of the 
herpes simplex virus (Nosadini et al., 2017). The rapid increase in the number of syndromes and 
autoantibodies identified over the past 10 years suggests that other autoimmune encephalitides 
have yet to be discovered (Dalmau et al., 2017; Dalmau et al., 2018). It is still unclear whether 
the molecular mechanism that leads to herpes simplex encephalitis is directly related to the 
episode of autoimmune encephalitis or whether it is the viral infection itself what triggers an 
autoimmune response via a different mechanism. 
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1.2.9 Genetics of HSE 
1.2.9.1 Lines of evidence 
The idea that HSE could be not only an infectious disease but also a genetic condition is a 
cornerstone of the genetic theory of infectious diseases (Casanova et al., 2012; Casanova, 
2015a; Casanova, 2015b). The field of human genetics of infectious diseases started to gain 
weight in the early 1950s with the birth of the modern cellular and molecular biology. Clinical 
geneticists started to describe primary immunodeficiencies (PIDs). PIDs were then considered 
rare, Mendelian diseases with complete penetrance caused by numerous recurrent, and 
opportunistic infections that presented with evident immunological abnormalities (Casanova & 
Abel, 2007). The first three PIDs that described a selective predisposition to a single infectious 
agent were epidermodysplasia verruciformis (a predisposition to oncogenic human papillomavirus 
infection), membrane attack complement defects (a predisposition to Neisseria), and X-linked 
lymphoproliferative disease (a predisposition to Epstein-Barr virus) (Casanova et al. 2013; Orth 
et al., 2008; Picard et al., 2006). These studies paved the way for the discovery, in the 1990s and 
beyond, of mutations underlying selective predisposition to various other infections, including 
mycobacterial disease, pneumococcal disease, chronic mucocutaneous candidiasis, and HSE 
(Jouanguy et al., 1996, Newport et al., 1996).  
HSE is one of the most remarkable examples of an isolated pediatric condition shown to result 
from a monogenic inborn error of immunity. Patients with myeloid and lymphoid PIDs, including 
children with no T cells, are not particularly susceptible to HSE. The disease is sporadic in most 
cases, with very few multiplex kindreds reported. However, a high frequency of parental 
consanguinity (12%) observed in a French survey (Abel et al., 2010) suggested that HSE could 
indeed occur due to single-gene inborn errors of immunity displaying incomplete clinical 
penetrance. 
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Last but not least, the beginning of the 21st century came with a few reports of rare cases of 
patients with complex clinical phenotypes that included HSE in which an inborn error of immunity 
had been identified. NEMO and STAT1 mutations leading to, respectively, impaired IFN-𝛾 and 
IFN-𝛼/𝛽 production and abolished IFN-𝛾 and IFN-𝛼/𝛽 responses were found in two children with 
syndromic HSE who also suffered from mycobacterial infections (Dupuis et al., 2003; Puel et al., 
2006).  
1.2.9.2 Patients with known genetic etiologies: the base camp 
The first genetic etiology of HSE to be identified was autosomal recessive UNC-93B deficiency, 
resulting in an impairment of cellular responses to the four intracellular Toll-like receptors (TLRs), 
including TLR3 (Casrouge et al., 2006). Involvement of the TLR3 pathway was then suspected, 
because IRAK-4- and MyD88-deficient patients, whose cells do not respond to TLR7–9 agonists, 
are not prone to HSE (Casanova et al., 2011; Ku et al., 2007; Picard et al., 2003; Picard et al., 
2010; von Bernuth et al., 2008). TLR3 was formally implicated in the disease when autosomal 
dominant and autosomal recessive TLR3 deficiencies were discovered in other patients with HSE 
(Zhang et al., 2007; Guo et al., 2011; Lim et al., 2014).  
 
Soon after, other molecules downstream TLR3 were described as genetic etiologies of 
HSE: TRIF, TRAF3, TBK1, and IRF3 mutations were found in some HSE patients (Sancho-
Shimizu et al., 2011; Perez de Diego et al., 2010; Herman et al., 2012, Andersen et al., 2015). 
These seminal studies provided the first explanation for the molecular pathogenesis of forebrain 
HSE in a sizable fraction of patients: HSV-1 produces viral double-stranded RNA (dsRNA) during 
its replication, this dsRNA is recognized by TLR3 inducing the activation of the IRF3 and NF-κB 
pathways via TRIF, leading to the production of IFN-α/β and IFN-λ and other cytokines. TLR3, 
UNC-93B, TRIF, TRAF3, TBK1, and NEMO deficiencies are associated with impaired IFN-α/β 
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and IFN-λ production, particularly during HSV-1 infection; while STAT1 deficiencies are 
associated with impaired IFN-α, -β, and -λ responses (Figure 1).  
 
Besides, a critical role of neuron and oligodendrocyte cell-intrinsic TLR3-mediated immunity in 
the defense against HSV-1 infection of the central nervous system has been further proposed 
(Lafaille et al., 2012). In contrast, iPSC-derived trigeminal neurons are naturally permissive to 
HSV-1 infection, regardless of their TLR3 genotype (Zimmer et al., 2018). 
 
More recently, forward genetic studies performed in our cohort of HSE patients lead to the 
identification of novel and more striking genetic etiologies by means of genetic homogeneity:  
 
AD mutations in SNORA31 have been associated with forebrain HSE, although no evidence 
suggests that it is linked to the TLR3 pathway (Lafaille et al., 2019) (Figure 1). SnoRNA31 directs 
the isomerization of uridine residues to pseudouridine in position 218 of the 18S ribosomal RNA 
(rRNA) and position 3713 of the 28S rRNA (Kiss et al., 2004). Studies with human pluripotent 
stem cell (hPSC)-derived cortical neurons showed that snoRNA31 is produced and functional in 
human cortical neurons that acts as a restriction factor for HSV-1.  
 
Likewise, inborn errors of RNA lariat metabolism due to mutations in DBR1 have been shown to 
cause brainstem HSE in a TLR3-independent manner, disrupting cell-intrinsic and tissue-specific 
immunity to HSV-1 and other viruses (Zhang et al., 2018) (Figure 1). The underlying molecular 
mechanism remains elusive. The accumulation of RNA lariats could impair host cell recognition 
of the virus, thereby damaging cell-intrinsic mechanisms against viral infection. Alternatively, 
DBR1 could regulate the processing of host or viral RNA lariats (Han et al., 2017; Murray et al., 
2014; Galvis et al., 2017) 
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Figure 1. Schematic representation of the known genetic etiologies of HSE. In dark blue, described 
genetic etiologies underlying forebrain HSE (UNC93B, TLR3, TRIF, TRAF3, TBK1, IRF3 and SNORA31). 
In yellow, the only known genetic etiology to underlie brainstem HSE (DBR1). In green, genetic etiologies 





1.2.9.3 Patients without known genetic etiologies: the challenge 
The advent of next-generation sequencing (NGS) technologies has clearly facilitated the 
discovery of new disease-causing variants in patients with all types of PIDs (Meyts et al., 2016), 
including HSE. Still, only a small fraction of the patients in our HSE cohort carry mutations in the 
aforementioned genes, probably due to the complex genetic architecture of the disease (i.e low 
clinical penetrance). We hypothesize that other single-gene inborn errors of immunity are yet to 
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We currently have a cohort of ~400 patients (and we are happy to recruit as many as possible) 
and multiple strategies are being pursued to analyze the whole-exome sequencing data of the 
patients to further understand the molecular mechanism(s) that underlie the genetic predisposition 
of the disease. These approaches include both forward and reverse genetic strategies. 
For the purpose of this thesis, we searched for novel HSE-causing candidate genes under an 
autosomal recessive (AR) mode of inheritance, following an unbiased genome-wide approach, 
and identified compound heterozygous RIPK3 mutations in one patient. 
 
1.3  Receptor Interacting Protein Kinase 3 (RIPK3) 
1.3.1  Regulation of necroptosis 
RIPK3 was first described in 1999 independently by two groups (Yu et al., 1999; Sun et al., 1999)  
as an apoptosis-inducing molecule that belonged to the RIP family of kinases. Back then, the 
different types of programmed cell death were poorly understood and it would take almost a 
decade until RIPK3 was rebranded as the key regulator of the necroptotic pathway (Declercq et 
al., 2009).  Traditionally, pathologists had discriminated only two types of cell death: apoptosis 
and necrosis, and they were differentiated based on their morphological properties. Apoptosis 
was defined by cell shrinking, the appearance of membrane blebs called apoptotic bodies, and 
condensation of chromatin; while necrosis was associated with cell and organelle swelling and 
limited chromatin condensation. Apoptosis was believed to be the only form of regulated cell death 
while necrosis was seen as the result of a trauma or injury. In the late nineties and early 2000s, 
studies on TNFR1, FAS, caspases and RIPK proteins started to suggest that other forms of cell 
death could share morphological similarities to necrosis but still be regulated by cellular programs 
(Vercammen et al., 1997; Vercammen et al., 1998; Holler et al., 2000; Degterev et al., 2005); and 
necroptosis started to appeared as a caspase-8 independent regulated form of cell death 
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morphologically similar to necrosis. The role of RIPK1 and RIPK3 in necroptosis was highlighted 
at the end of the decade with the identification of RIPK1 as the target of a group of small molecules 
called necrostatins in 2008 (Degterev et al., 2008), and the redefinition of RIPK3 as the key 
regulator of this new type of cell death in 2009 (Cho et al., 2009; Zhang et al., 2009; He et al., 
2009). RIPK3 has been intensively studied ever since due to its key role in necroptosis (Newtown 
et al., 2015).  
 
1.3.2 RIPK3 signaling 
1.3.2.1 TNFR1-induced RIPK3 mediated signaling 
Upon ligand binding, TNFR1 recruits RIPK1 and other molecules in what is known complex I 
(Micheau et al., 2003). This interaction occurs between either the intracellular death domain (DD) 
of TNFR1 and the DD of RIPK1 or indirectly through the DD of TRADD (Ermolaeva et al., 2008; 
Pobezinskaya et al., 2008). cIPAs ubiquitylate RIPK1 and likely other molecules of the complex I 
(Varfolomeev et al., 2008; Mahoney et al., 2008) creating a scaffold for the recruitment of TAB1-
TAB2/3-TAK1 and LUBAC (Cheung et al., 2004; Kanayama et al., 2004; Tokunaga et al., 2011; 
Ikeda et al., 2011; Gerlach et al., 2011). Linear ubiquitin chains regulated by LUBAC leads to the 
recruitment of the IκB kinase (IKK) complex, known as NEMO (Rahighi et al., 2009; Lo et al., 
2009). Once TAK1 and NEMO are active, they signal activation of the kinases JNK, p38, and ERK 
as well as NF-κB transcription factors, culminating in the expression of proinflammatory genes 
(Newtown et al., 2012) (Figure 2). If this TNFR1-mediated cascade is compromised, RIPK1, 
TRADD and other molecules of the complex I move into cytoplasmic complex II (Figure 2) 
(Micheau et al., 2003). FADD gets recruited into the complex II through its C-terminal DD and 
then its N-terminal death effector domain (DED) can bind to a DED in procaspase-8 and/or its 
catalytically inactive homolog FLIP (Dickens et al., 2012; Schleich et al., 2012; Majkut et al., 2014). 
If FLIP is scarce, then autoprocessing of caspase-8 homodimers within complex II triggers 
apoptosis. 
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Complex II signaling can also be disrupted through caspase-8 inhibition. This inhibition would 
then lead to the activation of RIPK3 (in the cell types where RIPK3 is expressed) (Cho et al., 
2009; Zhang et al., 2009; He et al., 2009), and its substrate, mixed lineage kinase-like (MLKL) 
(Sun et al., 2012; Zhao et al., 2012; Murphy et al., 2013; Wu et al., 2013) eventually triggering 
necroptosis. In this signaling cascade, RIPK3 uses RIPK1 as a cytosolic platform for the activation 
of necroptosis. RIPK1 and RIPK3 bind through their RIP Homotipic Interaction Motif (RHIM) 
domain (Sun et al., 2002) and this interaction eventually leads to the autophosphorylation of 
RIPK3 (Wu et al., 2014). Phosphorylated RIPK3 recruits and then phosphorylates MLKL within 
its C-terminal pseudokinase domain (Chen et al., 2013). MLKL is then transported to the 
membranes and leads to necroptotic cell death by a poorly understood mechanism that involves 
the disruption of the membrane through the creation of pores (Wang et al., 2014; Su et al., 2014; 
Cai et al., 2014). 
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Figure 2. TNFR1-mediated RIPK3 signaling pathway (Newton, K., & Manning, G. 2016). Upon TNF 
binding to its receptor, complex I (a mix of adaptor proteins, protein kinases and ubiquitin kinases) is formed. 
Ubiquitylation and phosphorylation events lead to the activation of NF-kB and mitogen activated protein 
kinases, resulting in expression of prosurvival and proinflammatory genes. When complex I is internalized 
and shifts to form complex II, two types of cell death can occur, apoptosis and necroptosis. The type of cell 
death is determined by caspase-8 activity, when active, the cell die by apoptosis. If compromised, 
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1.3.2.2 PRR-induced RIPK3 mediated signaling 
Although RIPK3 has been most extensively investigated in the context of TNFR1 signaling, it can 
also be activated by some pathogen recognition receptors (PRRs) (TLR3, TLR4, and ZBP1) (He 
et al., 2011; Kaiser et al., 2013; Upton et al., 2013; Upton et al., 2010). TLR3 and TLR4 respond 
to double-stranded RNA and lipopolysaccharide (LPS), respectively, by recruiting the RHIM-
containing adaptor protein TRIF. The RHIM in TRIF can engage the RHIM in RIPK1 (Meylan et 
al., 2004) or RIPK3 (Kaiser et al., 2005). Interestingly, the kinase activity of RIPK1 is required for 
TLR3- or TNFR1-induced necroptosis in macrophages (He et al., 2011; Kaiser et al., 2013), but 
is dispensable for TLR3-induced necroptosis in endothelial and fibroblastic cells (Kaiser et al., 
2013). DAI, also known as ZBP1, is an intracellular PRR that recognizes double-stranded RNA. 
It also contains a RHIM domain and can directly activate  RIPK3 (Upton et al., 2012). RIPK3 
activation leads to autophosphorylation and phosphorylation of MLKL, which is translocated to 
the membranes of the organelles and the membrane eventually disrupting their homeostasis and 
leading to a necrotic-like cell death similar to the one mediated by the TNFR1. 
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Figure 3. PRR-induced RIPK3 mediated signaling pathway (Newton, K., & Manning, G. 2016). TLR3 
and TLR4 are activated by double-strand RNA (dsRNA) and lipopolysaccharide (LPS), respectively. 
Recruitment of the adaptor protein TRIF to TLR3 or TLR4 within endolysosomes facilitates engagement of 
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1.3.3 RIPK3 in the context of viral infections 
Hallmark studies using vaccinia virus raised the notion that viral-induced necroptosis contributes 
to host defense (Li et al., 2000). A plethora of evidence has supported this concept ever since 
and it is widely accepted now that RIPK3-mediated cell death can be triggered by various viral 
agents including influenza A virus (IAV) (Nogusa et al., 2016), human and murine 
cytomegalovirus (HCMV and MCMV) (Upton et al., 2010), herpes simplex viruses (HSV-1 and 
HSV-2) (Guo et al., 2015; Huan et al., 2015), and the aforementioned vaccinia virus (Cho et al., 
2009) among others. More recent studies have also shown that, unlike the canonical function 
normally ascribed to RIPK3, ZIKV and WNV infections of the central nervous system are also 
combated by murine RIPK3 in a necroptosis-independent manner (Daniels et al., 2017; Daniels 
et al., 2019). Overall, these seminal studies depict RIPK3 as a pleiotropic antiviral molecule whose 
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2. MATERIALS AND METHODS 
 
2.1 Human subjects 
 
Informed consent was obtained in France, in accordance with local regulations and a human 
subjects research protocol approved by the institutional review board (IRB) of INSERM. 
Experiments using samples from human subjects were conducted in the United States, in 
accordance with local regulations and with the approval of the IRB of The Rockefeller University. 
 
 
2.2 Cell culture 
Primary human fibroblasts were obtained from skin biopsy specimens from controls and P1 and 
were cultured in DMEM medium (GIBCO BRL, Invitrogen) supplemented with 10% fetal calf 
serum (FCS) (GIBCO BRL, Invitrogen). To create immortalized SV40-transformed fibroblast cell 
lines (SV40-fibroblasts), 4 mg of a plasmid containing T antigen DNA was used to transfect about 
5 millions of cells by electroporation. The cells were then placed into two fresh 75 cm2 flasks 
containing 12 mL of DMEM medium (GIBCO BRL, Invitrogen) supplemented with 10% FCS 
(GIBCO BRL, Invitrogen). SV40-fibroblasts clones appeared after about 15 days. They were then 
grown and passaged for experimental usage. To create Epstein-Barr virus (EBV)-transformed B 
cell lines (EBV-B), fresh blood samples were obtained from controls and P1, peripheral blood 
mononuclear cells (PBMC) were isolated on Ficoll-Paque PLUS (GE Healthcare, USA). PBMCs 
were then infected with EBV, and kept in culture in RPMI medium (GIBCO BRL, Invitrogen) 
supplemented with 10% FCS (GIBCO BRL, Invitrogen). EBV-B clones will appear in about 15 
days. They could then be grown and passaged for experimental usage. HEK293T cells (ATCC) 
were maintained in DMEM supplemented with 10% FCS. HeLa cells (ATCC) were maintained in 
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DMEM supplemented with 10% FCS. HT29 cells (ATCC) were maintained in McCoy medium. 
Transfected cell lines were generated by transfecting pTRIP or mock vector (Luc), with X-
tremegene 9, according to the manufacturer’s protocol. HT-29 cells stably expressing pTRIP 
constructs were generated by lentiviral transduction. These cells were kept in culture under 
puromycin selection (10 µg/ml).  
 
2.3 Whole-exome sequencing 
 
Whole-exome sequencing (WES) was performed on genomic DNA extracted from whole blood 
from P1 by the New York Genome Center, using an Illumina HiSeq 2500 machine and an Agilent 
71Mb SureSelect exome kit.  
 
 
2.4 Sanger sequencing of genomic DNA 
 
Genomic DNA Samples from controls, P1 and her parents were used as a template for the 
amplification of 300-600-bp regions encompassing the mutation by PCR with site-specific 
oligonucleotides. Amplicons were sequenced with BigDye Terminator technology on an ABI 3730 
DNA sequencer. SnapGene was used for sequence analysis.  
The sequences of the primers used are as follows: 
R422* forward: GATTCGATGGCCCAACCTCC 
R422* reverse: GCCCCCTGCAAACAGCACAG 
P493fs9* forward: GACCGCTCGTTAACATATAC 
P493fs9* reverse: GGCCAGACTGCCCTAGAAG 
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2.5 Western blots 
 
Total cell extracts were prepared from primary fibroblasts, SV40-fibroblasts and B-EBV cells from 
healthy controls and P1 or HEK293T cells, HeLa cells or HT29 cells. Equal amounts of protein 
from each sample were separated by SDS-PAGE and blotted onto polyvinylidene difluoride 
membrane (Bio-Rad, Hercules, CA). These PVDF membranes were then probed with antibodies 
against RIPK3, RIPK1, MLKL, P-MLKL. Membranes were stripped and reprobed with an antibody 
against GAPDH (Santa-Cruz, USA), to control for protein loading. Antibody binding was detected 
by enhanced chemiluminescence (ECL; Amersham-Pharmacia-Biotech). 
 
 
2.6 Measurement of RIPK3 transcript levels by RT-qPCR 
 
Gene expression was assessed by measuring transcript levels. Total RNA was extracted from 
SV40-fibroblasts, EBV-B cells and HEK293T cells. RNA was reverse-transcribed directly, 
with random hexamers (Invitrogen) (for RNA from SV40-fibroblasts or EBV-B cells) or with the 
SuperScript III Cells-Direct kit (Life Technologies, for HEK293T cells), to determine mRNA levels 
for RIPK3. Reverse transcription-quantitative PCR (RT-qPCR) was performed with Applied 
Biosystems 2 x universal Taqman reaction mixture and Assays-on-Demand probe/primer 
combinations, in an ABI PRISM 7700 Sequence Detection System. GUS and GAPDH genes were 
used for normalization. Hs01011171_g1 (RIPK3 exons 2-3) and Hs01011177_g1 (RIPK3 exons 
9-10) probes were used. Results are expressed according to the ΔCt method, as described by 
the manufacturer. Two independent experiments were performed, for measurement of RIPK3 
transcript levels in primary fibroblasts, SV40-fibroblasts or EBV-B cells, technical duplicates were 
used in each experiment. For measurement of RIPK3 transcript levels in HEK293T cells, one 
experiment was performed using biological duplicates for each condition. 
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HELA cells were subjected to transient transfection with WT or mutant RIPK3 using X-
tremeGENE9 transfection reagent (Sigma-Aldrich). After 48h of incubation, cells were fixed with 
4% paraformaldehyde for 15 min at 37°C, washed 3 times with PBS, permeabilized with 0.1% 
Triton and blocked with 0,1% Triton containing 6% Donkey serum for 1h. The cell cultures were 
stained overnight with the RIPK3 primary antibody (Santa-Cruz, USA). Cells were washed 3 times 
with PBS and incubated with secondary antibodies: anti-mouse Alexa 633 (Invitrogen). Cells were 
washed 3 times with PBS and mounted in DAPI containing Prolong Gold mounting media (Thermo 
Fisher Scientific). Slides were examined with a confocal laser microscope (Confocal Leica SP8 
gSTED). All images were acquired with APO CS2 63x/1.4 OIL objectives. Images were exported 
as tiff files and image analysis was performed with ImageJ software. For each independent 
experiment, 5-12 cells were analyzed per condition. Each field was selected from DAPI-positive 
staining, which was used for defining the nuclear region (NR). 
 
 
2.8 Necroptosis induction  
 
For the detection of MLKL phosphorylation, necroptosis was induced by combined treatment with 
PBZ (poly(I:C), 25ug/ml; BV6, 1uM; z-VAD.fmk, 20uM) or TBZ (TNF-a, 1000 units/ml, BV6, 1uM; 
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2.9 Cell viability 
 
Cells (5,000 cells/well) were seeded into Corning 96-well tissue culture plates. 16–24 h post-
seeding. Cells were treated with the indicated reagents, and solvent, DMSO, was kept constant 
for all experiments. 30 ng/ml TNF, 5 uM BV6, and/or 25uM -VAD-fmk were used. Cell viability 
was assessed by measuring the intracellular levels of ATP using the Cell Titer-Glo luminescent 




2.10 TLR3 agonists 
 
We used a synthetic analog of dsRNA, polyinosine-polycytidylic acid (poly(I:C)), as a nonspecific 
agonist of TLR3 and MDA5/RIG-I. SV40-fibroblast cells were activated in 24-well plates, at a 
density of 100,000 cells/well, for 24 hours with poly(I:C) at 1, 5 and 25 μg/mL. Cells were 
stimulated with 25μg/mL of poly(I:C) in the presence of Lipofectamine 2000 to activate 






Levels of IFN-a, -β, -λ and IL-6 production were assessed by ELISA after 24 h of cell stimulation. 
Separate ELISAs were performed for each of IFN-a (eBioscience, USA), IFN-β (PBL, USA), IFN-
λ (R&D Biosystems, USA), and IL-6 (eBioscience, the Netherlands), according to the kit 
manufacturer’s instructions. 
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3.1 A case of recurrent HSE and suspected post-herpetic autoimmune encephalitis 
We studied a patient (P1) born in France to non-consanguineous parents and presented at 6 
months of age with herpes simplex encephalitis. P1 was previously healthy and had received all 
recommended vaccinations. She presented with fever, a brief episode of loss of consciousness 
with hypotonia and an episode of right hemi-body seizure lasting 10 minutes. Lumbar puncture 
showed elevated protein content (0.45g/L) and elevated nucleated cells (53/mm3), mostly 
lymphocytes. PCR for herpes simplex virus (HSV1/2) was positive and CSF interferon levels were 
elevated (50U.I.). Electroencephalogram showed a left centro-temporal slowness, without 
paroxystic elements. Brain MRI showed a slight hypersignal in the left hemisphere (Figure 4). She 
was treated for 10 days with intravenous acyclovir and discharged after a good clinical evolution.  
A year later, she was readmitted to the hospital for another episode of HSE. She presented with 
elevated fever, seizures and abnormal level of consciousness. Lumbar puncture showed elevated 
protein content (0.57g/L) and elevated white blood cells (45/mm3). PCR for herpes simplex virus 
(HSV) was again positive. A CT scan showed bilateral frontal hypodense regions, predominantly 
in the right hemisphere with hemorrhagic foci. She was treated with intravenous acyclovir and 
admitted to the intensive care unit (ICU). During her hospitalization, she presents with persistent 
seizures, hypotonia and dysmetria. She was discharged after 3 weeks of acyclovir treatment, with 
neurological sequelae.  
A week later, she was again hospitalized for an episode of encephalitis strongly suggestive of 
auto-immune encephalitis. She presented with altered levels of consciousness, dysphagia and 
abnormal ventilation. Lumbar puncture showed elevated protein levels (1,32g/L), 10 white blood 
cells but negative PCR for HSV1/2. Brain CT scanner showed diffuse hypodense regions in both 
frontal lobes, both parietal lobes, right occipital lobe and basal ganglia. EEG was suggestive of a 
Thesis dissertation of Eduardo J. Garcia Reino 
Bi-allelic RIPK3 mutations in a patient with Herpes Simplex Encephalitis 
42 
reactive coma. She was treated with high dose intravenous steroids and acyclovir. She later 
developed movements disorders with dyskinesia and decreased level of consciousness. After 2 
weeks of treatment, a control MRI was performed showing T2 hypersignal predominantly in the 
white matter. She was discharged from the hospital with severe neurological consequences. 
 
 
                     
 
Figure 4. MRI images of the brain of the patient, showing lesions affection the right frontotemporal 
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3.2  Identification of bi-allelic RIPK3 mutations in the proband 
 
We tested our recurrent hypothesis that a single gene inborn error of immunity could underlie the 
clinical phenotype of the patient. To test this hypothesis, we perform Whole-exome sequencing 
(WES) on genomic DNA extracted from whole blood of P1. We then applied a filtering criteria 
according to an autosomal recessive mode of inheritance  and found 6 genes harboring 
homozygous or more than one heterozygous nonsynonymous mutations (figure 5 and tables 1 
and 2), among which we identified two heterozygous mutations p.Arg422* (R422*) and 
p.Pro493Thrfs*9 (P493fs9*) in RIPK3 encoding Receptor Interacting Protein Kinase 3 (RIPK3). 
RIPK3 is a likely candidate to underlie HSE from a biologically point of view. First, RIPK3 is able 
to signal downstream TLR3 via direct interaction with TRIF (He et al., 2011; Kaiser et al., 2013), 
which are both genetic etiologies of HSE. Second, RIPK3 is targeted by HSV-1 through interaction 
of the RHIM domain of RIPK3 with the RHIM domain of the viral protein ICP6 (Guo et al., 2015; 
Huan et al., 2015) . Last, RIPK3 has been shown to play an important role in viral restriction in 
the central nervous system (Daniels et al., 2017; Daniels et al., 2019). In fact, soon after we 
started this study of the role of RIPK3 in HSE, Katherine B. Ragan and Jason W. Upton made 
very similar observations to ours, and they independently predicted that mutations in RIPK3 could 
underlie HSE (Ragan & Upton; 2017).  
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Figure 5. Analysis of P1’s Whole-Exome sequencing. Filtering criteria applied to the Whole-Exome 
sequencing data of the patient under a potential autosomal recessive mode of inheritance. MQ, Mapping 
quality; VQ, variant quality; DP, combined depth across samples; MAF, minor alleles frequency; GDI, gene 
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Thesis dissertation of Eduardo J. Garcia Reino 
Bi-allelic RIPK3 mutations in a patient with Herpes Simplex Encephalitis 
45 
 
Gene Function Annotation Zygosis Allele 
frequency 
CADD 
CDC27 missense p.Trp644Arg het 0.002817 29.4 
CDC27 missense p.Tyr641Cys het 0.00702138 28 
PABPC1 missense p.Arg481Cys het 0.00380623 27.6 
PABPC1 missense p.Arg475Gln het 0.00189407 23.8 
PABPC1 missense p.Ile454Thr het 7.32E-04 20.8 
PABPC1 missense p.Phe409Leu het 4.68E-04 23.1 
PABPC1 missense p.Tyr408Phe het 8.76E-04 22.5 
PABPC1 stop-gained p.Glu345* het 0.00150455 40 
PCDHA1 missense p.Asn449His hom 0.00427296 23.8 
RIPK3 indel-frameshift p.Pro493fs het 0.00207218 24.2 
RIPK3 stop-gained p.Arg422* het 0.00105122 35 
ZNF208 missense p.Asp22Asn het 0.00267752 14.52 
ZNF208 missense p.Thr5Ile het 3.34E-05 11.56 
ZNF785 missense p.Val193Gly het 0.00753272 21.5 
ZNF785 missense p.Glu119Lys het 0.00751832 8.72 
 
 
Table 1. Homozygous and ‘compound heterozygous’ rare nonsynonymous variations found in P1 




Gene description Function Clinical significance 
Cell Division Cycle 27 
(CDC27) 
Subunit of the anaphase-
promoting complex (APC) 
Unknown 
Polyadenylate-binding 
protein 3 (PABPC3) 





Mediate cell-cell interaction Unknown 
Receptor-Interacting 




Zinc Finger Protein 208 
(ZNF208) 
Unknown Unknown 





Table 2. Characteristics of the genes that remained in the exome of P1 after filtering Whole-Exome 
Sequencing data. 
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Sanger sequencing of the patient and her parents confirmed both mutations in the patient, and 
revealed that the R422* variant was inherited from the mother and that the P493fs9* was inherited 
from the father (figure 6A and 6B), corroborating the true compound heterozygosity nature of the 
mutations. R422* and P493fs9* yield a minor allele frequency of 0.001568 and 0.002555, 
respectively, as reported in gnomAD (http://gnomad.broadinstitute.org/) (figure. 6C and table 3), 
where we found only one homozygous carrier for each variant out of the 140,312 sequenced 
individuals. The number of homozygous carriers of these variants in the general population is, 
therefore, compatible with the incidence and the penetrance of the disease. No other homozygous 
or compound heterozygous carrier of rare nonsynonymous variants was found in our in-house 
database (>6000 patients). Last, both variants have combined annotation-dependent depletion 
(CADD) (http://cadd.gs.washington.edu/) scores well above the mutation significance cutoff 
(MSC) of RIPK3 (http://pec630.rockefeller.edu:8080/MSC/) (figure 6C). probably because both of 
them are predicted to generate aberrant forms of the protein (figure 6D) Both combined, R422* 
and P493fs mutations may lead to AR RIPK3 deficiency underlying HSE. 
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Figure 6. Compound heterozygous RIPK3 mutations in a French girl from a non-consanguineous 
family. (A) Familial segregation of RIPK3 mutations in a nonconsanguineous French family. (B) 
Electropherogram showing the mutations in exons 8 and 9 in RIPK3 in P1 and her parents, respectively. 
(C) Representation of all homozygous nonsynonymous RIPK3 variants reported in gnomAD. The minor 
allele frequency and CADD score of each variant is shown. CADD MSC of RIPK3: the 95% confidence 
interval mutational significant cutoff CADD score of RIPK3. (D) Schematic representation of RIPK3 protein 
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3.3  Investigation of the alleles through plasmid mediated overexpression 
 
We studied the expression and function of the R422* and P493fs9* RIPK3 mutants through 
plasmid-mediated overexpression in HEK293T cells, which have very low endogenous level 
RIPK3 expression; HeLa cells; and RIPK3 knock-out (KO) HT29 cells. We first investigated the 
expression of the mutant alleles by transiently transfecting RIPK3 constructs in HEK293T cells. 
Compared with RIPK3 WT, both mutants resulted in normal mRNA production as assessed by 
RT-qPCR using two different probes (figure 7A). At the protein level, the mutants are predicted to 
codify proteins of a smaller molecular size: R422* would translate into a 46 kDa protein, and 
P493fs9* would translate into a 56 kDa protein, while the WT protein size is 57 kDa. When we 
analyzed the expression of the mutant alleles in HEK293T cells overexpressing the RIPK3 
plasmids, we observed that the encoded proteins were indeed truncated forms of RIPK3 (figure 
7B). In the case of R422*, the introduction of a premature stop codon led to the expression of a 
protein of ~46 kDa. In addition, R422* also showed an impaired autophosphorylation and 
cleavage, as the levels of expression of the N-terminus cleaved fragment are significantly lower 
when compare to the WT. On the other hand, the introduction of a frameshift mutation in the 
P493fs9* codified a protein of ~56 kDa, which is slightly smaller than the WT protein. Therefore, 
neither of the mutant constructs lead to reinitiation of translation (figure 7B).  We then examined 
the ability of the mutant alleles to induce NF-κB activity upon transient transfection in HEK293T 
cells, and we found that R422* but not P493fs9* was loss of function (figure C-E). In contrast, 
neither the expression nor the function was affected when we overexpressed RIPK3 constructs 
containing the common variants found in public databases (figure 8). 
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Figure 7. The mutant alleles encode truncated forms of the protein but only R422* is loss of function 
in terms of its NF-κB activation activity. (A) Wild-type (WT) and mutant RIPK3 mRNA levels in 
transfected HEK293T cells. Levels of WT, R422* or P493fs9* were assessed by RT-qPCR using a probe 
that binds exons 2-3 (left) and exons 9-10 (right) of RIPK3 cDNA. (B) Wild-type (WT) and mutant RIPK3 
protein levels in transfected HEK293T cells assessed by western blotting. RIPK3 protein was detected 
using a monoclonal antibody directed against the N terminus of RIPK3 and an monoclonal antibody directed 
against the C terminus of RIPK3. Results are representative of at least three independent experiments. (C) 
RIPK3 dependent NF-kB activity. HEK293T cells were cotransfected with NF-κB luciferase reporter plasmid 
(100 ng) and Renilla luciferase reporter plasmid (10 ng) with equal amounts (50ng, 25ng, and 12.5ng) of 
pTRIP EV, pTRIP RIPK3 WT and mutants, respectively. Cells were harvested at 24h post-transfection for 
Firefly and Renilla luciferase activity assay using the Dual-Luciferase Reporter Assay System (Promega). 
Firefly luciferase values were corrected for transfection efficiency with Renilla activity. (D) Wild-type (WT) 
and mutant RIPK3 dose-dependent mRNA levels in transfected HEK293T cells. Levels of WT, R422* or 
P493fs9* were assessed by RT-PCR. (E) Wild-type (WT) and mutant RIPK3 dose-dependent protein levels 
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Figure 8. Overexpression of constructs containing common RIPK3 variants show normal function 
and expression. (A) RIPK3 dependent NF-κB activity. HEK293T cells were cotransfected with NF-κB 
luciferase reporter plasmid (100 ng) and Renilla luciferase reporter plasmid (10 ng) with equal amounts 
(50ng) of pTRIP EV and RIPK3 constructs, respectively. Cells were harvested at 24h post-transfection for 
Firefly and Renilla luciferase activity assay using the Dual-Luciferase Reporter Assay System (Promega). 
Firefly luciferase values were corrected for transfection efficiency with Renilla activity. (B) RIPK3 mRNA 
levels in transfected HEK293T cells as assessed by RT-qPCR using a probe that binds exons 2-3. (C) 
RIPK3 protein levels in transfected HEK293T cells assessed by western blotting. RIPK3 protein was 




We interrogated the subcellular localization of the mutant alleles. To do that, we transfected HeLa 
cells with RIPK3 constructs and analyzed their localization by confocal microscopy. Similar to 
their WT counterpart, the mutants were detected in the cytoplasm (figure 9A). Because the 
mutants localized normally in the cytoplasm, we decided to study the capability of these alleles to 
interact with RIPK1, RIPK3 WT, with themselves, and with each other. Only P493fs9* was able 
to bind to their homolog monomers, although unable to bind to R422*. P493fs9* also maintained 
the ability to the RIPK3 WT, as well as with RIPK1 WT (Fig. 9B and 9C), which is consistent with 
the fact that this construct contains an intact RIP Homotypic Interaction Motif (RHIM) domain, 
which is required for this interaction as well as the interaction of RIPK3 with the other RHIM-
containing proteins (RIPK1, TRIF, and ZBP1 in vertebrates and ICP6, ICP10 and M45 in 































































































Thesis dissertation of Eduardo J. Garcia Reino 
Bi-allelic RIPK3 mutations in a patient with Herpes Simplex Encephalitis 
51 
 
Figure 9. The mutant alleles are normally expressed in the cytoplasm but only P493fs9* can interact 
with other RHIM-containing constructs. (A) Wild-type (WT) and mutant RIPK3 subcellular localization in 
upon construct transfection in HeLa. Subcellular localization was obtained by confocal microscopy.  (B) 
Flag-tagged RIPK3 WT and mutant constructs were co-expressed with Myc-tagged RIPK1 WT in HEK293T 
cells, and whole cell lysates were immunoprecipitated with anti-Flag and anti-Myc beads, followed by 
immunoblotting with anti-flag or anti-Myc antibodies. Results are representative of three independent 
experiments. (C) Flag-tagged RIPK3 WT and mutant constructs were co-expressed with Myc-tagged RIPK3 
WT and mutant constructs in HEK293T cells, and whole cell lysates were immunoprecipitated with anti-
Flag and anti-Myc beads, followed by immunoblotting with anti-flag or anti-Myc antibodies. Results are 
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Next, we investigated the expression and function of the mutants after retroviral transduction in 
HT29 RIPK3 knock out cells. Similar to the results obtained in HEK293T cells, both mutants 
encoded aberrant proteins. However, in this system P493fs9* showed lower levels of protein 
expression (Fig. 10A), although normal levels of mRNA expression (Figure 10B), suggesting that 
this mutant construct could be less stable than the WT protein.  
Finally, we investigated the ability of the mutants to induce the phosphorylation of MLKL, a main 
substrate of RIPK3, and the effector molecule of the necroptotic pathway (Sun et al., 2012). HT29 
RIPK3-/- cells transduced with RIPK3 WT, and mutant constructs were stimulated with 
combinations of the caspase inhibitor z-VAD, the smac-mimetic BV6, and either poly(I:C) (PBZ) 
or TNF-a (TBZ), as previously described (Guo et al., 2015). We observed that R422* but not 
P493fs9* was loss of function in terms of MLKL phosphorylation (p-MLKL) both via TLR3 (figure 
10C) and via TNFR1 (figure 10D). Consistent with these results, cell viability of HT29 RIPK3-/- 
cells transduced with WT and P493fs9*, but not with R422*, was severely impaired upon PBZ 
and TBZ stimulation (Figures 10E and 10F). 
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Figure 10. RIPK3 overexpression in HT29 RIPK3-/- cells. (A) Wild-type (WT) and mutant RIPK3 protein 
levels in retro-transduced  HT29 RIPK3-/- cells. Levels of WT, R422* or P493fs9* were assessed by western 
blotting. Results are representative of at least 3 independent experiments. (C) MLKL phosphorylation after 
PBZ stimulation in HT29 RIPK3-/- stably transfected with RIPK3 WT and mutant constructs. Results are 
representative of two independent experiments. (D) MLKL phosphorylation after TBZ stimulation in HT29 
RIPK3-/- stably transfected with RIPK3 WT and mutant constructs. Results are representative of three 
independent experiments. (E) Cell viability assay was performed upon PBZ stimulation in HT29 RIPK3-/- 
transduced with RIPK3 WT and mutant constructs. (F) Cell viability assay was performed upon TBZ 
stimulation in HT29 RIPK3-/- transduced with RIPK3 WT and mutant constructs. (A, C and D) are 
representative of at least three independent experiments. (E and F) are mean values of three independent 




3.4 Study of mRNA and protein RIPK3 expression in the patient cells 
 
We next interrogated the impact of the mutations on the RIPK3 mRNA and protein expression in 
cells from the patient. The overall amounts of RIPK3 mRNA from B-EBV cells, SV40-fibroblasts, 
and primary fibroblasts from P1 were still within the range of controls (figures 11A-C), probably 
because of the interindividual variability of RIPK3 mRNA observed in these cell types. 
Nevertheless, TOPO-cloning of cDNA generated from gDNA of the patient fibroblasts revealed 
that RIPK3 mRNA containing R422* mutant represented ~2.75% of the total amount of transcripts 
and P493fs9* the ~97.25% left (figure 11D). R422* might, therefore, lead to nonsense mRNA 
decay. 
 
In contrast, RIPK3 protein expression was undetectable in the patient B-EBVs, SV40-fibroblasts 
and primary fibroblasts with two different antibodies (figures 11E-G). These data, in combination 
with the results obtained in overexpression, suggest that the total amount of RIPK3 protein 
expression in the patient cells might be severely reduced due to (i) nonsense mRNA decay of 
R422* and (ii) protein instability of P493fs9*.  
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Figure 11. The RIPK3 mutant alleles are loss of expression at endogenous levels by different 
mechanisms. (A) RIPK3 mRNA levels assessed by RT-qPCR in immortalized B-EBVs from controls and 
P1. (B) RIPK3 mRNA levels assessed by RT-qPCR in immortalized SV40-fibroblasts from controls and P1. 
(C) RIPK3 mRNA levels assessed by RT-qPCR in primary fibroblasts from controls and P1.(A-C) Results 
represent the average of two experiments with two biological duplicates. (D) Relative abundance (%) of 
RIPK3 cDNA generated from mRNA extracted from patient’s immortalized SV40-fibroblasts assessed by 
TOPO-TA cloning. (E) RIPK3 protein levels in immortalized B-EBVs from controls and P1.. (F) RIPK3 
protein levels in primary fibroblasts from controls and P1 assessed by western blotting. (G) RIPK3 protein 
levels in SV40-fibroblasts from controls and P1 assessed by western blotting.  (E-G) RIPK3 protein was 
detected using a monoclonal antibody directed against the N terminus of RIPK3 and a monoclonal antibody 





3.5 MLKL phosphorylation is broadly impaired in P1 and selectively impaired via TLR3 in 
other HSE patients with mutations in the TLR3 pathway 
 
In spite of having certain pleiotropy as a restriction factor during viral infection (Daniels et al., 
2017; Daniels et al., 2019), RIPK3 is well-known for its ability to phosphorylate MLKL and, in a 
broader sense, regulate necroptosis (Newton & Manning., 2016). In order to decipher whether 
the patient mutations would impair RIPK3-mediated signaling, we decided to investigate whether 
MLKL could be phosphorylated in immortalized SV40-fibroblasts from the patient either via TLR3 
or TNFR1. To this end, SV40-fibroblasts from controls and from the patient were stimulated with 
PBZ and TBZ (figure 12A) using HT29 cells as a positive control (figure 12B), similar to the 
conditions used to test the ability of the alleles to induce necroptosis. The phosphorylation of 
MLKL was detected in control fibroblasts upon PBZ and TBZ stimulation, but not in the patient 
SV40-fibroblasts, suggesting that the mutants disrupt RIPK3 mediated signaling at endogenous 
levels. To further confirm our hypothesis, we decided to rescue this phenotype by transiently 
transfecting RIPK3 WT plasmid into the patient’s SV40-fibroblasts. Upon transfection of the 
RIPK3 WT plasmid,  levels of MLKL phosphorylation  were detectable after stimulation with both 
PBZ and TBZ stimulation  (Figures 12C and 12D) indicating that the abrogated expression and 
function of the RIPK3 mutants carried by the patient were indeed accountable for the impaired 
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RIPK3-mediated signaling observed in the patient cells. Interestingly, levels of full-length RIPK3 
protein expression in transfected patient cells decreased after stimulation, probably because of 
the cleavage that follows the activation of the protein. Taken together, these results suggest that 
the compound heterozygous RIPK3 mutations of the proband indeed lead to autosomal recessive 
RIPK3 deficiency, at least in SV40-fibroblasts. 
 
Since other HSE patients carry mutations in the TLR3 responsive pathway, and RIPK3 can signal 
downstream TLR3, we contemplated the possibility that the inborn errors of the TLR3 pathway 
previously described in other HSE patients could present with disrupted RIPK3-mediated 
signaling. To test this hypothesis, we interrogated dermal fibroblasts from patients with autosomal 
recessive (AR) complete TLR3, TRIF, and UNC93B deficiency and autosomal dominant (AD) 
partial TBK1 deficiency in terms of MLKL phosphorylation upon TBZ and PBZ stimulation. 
Consistent with the literature, TLR3-, TRIF- and UNC93B-deficient fibroblasts were unable to 
phosphorylate MLKL via TLR3 (figure 12D) but were able to phosphorylate MLKL via TNFR1 
(figure 12E), showing a selective impairment on its ability to induced necroptosis, restricted to 
TLR3 but otherwise normal. In contrast, fibroblasts from a HSE patient with AD TBK1 deficiency 
were able to phosphorylate MLKL normally via both TLR3 and TNFR1 (Figures 12D and E). These 
data suggest that either TBK1 is, at least to some extent, redundant in the mediation of 
necroptosis in fibroblasts, or that the partial defect of the mutant allele us not sufficient to impair 
the activation of RIPK3 and consequent phosphorylation of MLKL. 
 
Overall, our dataset indicates that, in addition to the decreased TLR3-mediated production of 
interferons and activation of the NF-kB pathway, patients with mutations in the TLR3 pathway 
upstream RIPK3 (i.e. UNC93B, TLR3, and TRIF) also present with an abrogated signaling in 
another branch of the TLR3 circuit that is mediated by RIPK3, which might account, at least to 
some extent, for the HSE phenotype observed in those patients. 
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Figure 12. RIPK3-dependent signaling is broadly impaired in P1 and selectively impaired in other 
HSE patients via TLR3. (A) SV40-fibroblasts from two healthy controls and P1 were stimulated with either 
PBZ or TBZ. (B) HT29 WT and HT29 RIPK3-/- cells were stimulated with either PBZ or TBZ. (C) 
Complementation of MLKL phosphorylation via TLR3 in the patient SV40-fibroblasts. SV40-fibroblasts from 
a control and P1 either left untransfected or transiently transfected with a mock vector (Luc) or RIPK3 WT, 
were stimulated with PBZ. (D) Complementation of MLKL phosphorylation via TNFR1 in the patient SV40-
fibroblasts. SV40-fibroblasts from a control and P1, either left untransfected or transiently transfected with 
a mock vector (Luc) or RIPK3 WT, were stimulated with TBZ. (A-D) Cell lysates were prepared and Western 
blotting was performed with antibodies against p-MLKL, total MLKL, RIPK3 and GAPDH.  (E) MLKL 
phosphorylation via TLR3 in HSE patients with mutations in the TLR3 responsive pathway. SV40-fibroblasts 
from a control, P1, and HSE patients with AR TLR3, TRIF, and UNC93B deficiency and AD TBK1 deficiency 
were stimulated with PBZ. (E) MLKL phosphorylation via TNFR1 in HSE patients with mutations in the TLR3 
responsive pathway. SV40-fibroblasts from a control, P1, and HSE patients with AR TLR3, TRIF, and 
UNC93B deficiency and AD TBK1 deficiency were stimulated with TBZ.  (E-F) Cell lysates were prepared 
and Western blotting was performed with antibodies against p-MLKL, total MLKL, and GAPDH. (A-F) 
Western blotting results are representative of at least 3 independent experiments.  
PBZ    -   +   -  +  -   +   -  +   -   +  -   +  
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3.6 Human RIPK3-deficient fibroblasts show normal levels of cell viability and interferon 
production. 
 
We next tested whether the impaired RIPK3-mediated signaling that leads to a lack of MLKL 
phosphorylation would result in decreased necroptotic signaling. We stimulated SV40-fibroblasts 
from controls, the patient, and patients with AR TLR3 and TRIF deficiency with combinations of 
Poly(I:C), TNF-a, BV6 and z-VAD and analyzed the viability of these cells. Although the cell 
viability was decreased in controls and patient cells upon stimulation with Poly(I:C) or TNF-a in 
combination with BV6, which is considered a marker of apoptotic cell death, PBZ and TBZ 
stimulations barely decrease the cell viability in these cells (Figures 13A and 13B). These results 
are consistent with previous reports that indicate that the levels of expression of RIPK3 in human 
fibroblasts are not sufficient to cross the threshold of MLKL phosphorylation that would lead to 
necroptotic cell death (Omoto et al., 2015).  
Last, since other patients with mutations in the TLR3 responsive pathway usually show an 
impaired or abolished TLR3-dependent production of interferons and other cytokines, we tested 
whether RIPK3-deficient fibroblasts could produce interferons and other cytokines via TLR3. 
Interestingly, TLR3-mediated production of both interferon-l and interferon-b as well as the 
production of IL-6 was normal in the patient fibroblasts (figures 13C-E), indicating that RIPK3 is 
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Figure 13. Human RIPK3-deficient fibroblasts show normal levels of cell viability and TLR3-
mediated interferon production. (A) Susceptibility of SV40-fibroblasts to TLR3-mediated cell death. 
SV40-fibroblasts from three different controls, P1, and HSE patients with AR TLR3, and TRIF deficiency 
were stimulated with combinations of Poly(I:C), IAP antagonist/SMAC mimetic, BV6 (S; 5M), and/or 
caspase inhibitor, Z-VAD-fmk (V; 25M), alone or in the combinations shown. Viability was determined by 
measuring intracellular ATP as percentage of vehicle (0.1% DMSO) of each genotype. (B) Susceptibility of 
SV40-fibroblasts to TNFR1-mediated cell death. SV40-fibroblasts from three different controls, P1, and 
HSE patients with AR TLR3, and TRIF deficiency were stimulated with combinations of TNF-a, IAP 
antagonist/SMAC mimetic, BV6 (S; 5M), and/or caspase inhibitor, Z-VAD-fmk (V; 25M), alone or in the 
combinations shown. Viability was determined by measuring intracellular ATP as percentage of vehicle 
(0.1% DMSO) of each genotype. (C) SV40-fibroblasts from three healthy controls, P1 and a TLR3-/- HSE 
patient were stimulated with different doses of poly(I:C). Poly(I:C) in combination with lipofectamine served 
as positive control for TLR3-independent engagement of poly(I:C). Supernatants were collected 24h after 
stimulation and IFN-l ELISA was performed. (D) SV40-fibroblasts from three healthy controls, P1 and a 
TLR3-/- HSE patient were stimulated with different doses of poly(I:C). Poly(I:C) in combination with 
lipofectamine served as positive control for TLR3-independent cytokine production. Supernatants were 
collected 24h after stimulation and IFN-b ELISA was performed. (E) SV40-fibroblasts from three healthy 
controls, P1 and a TLR3-/- HSE patient were stimulated with different doses of poly(I:C). Poly(I:C) in 
combination with lipofectamine served as positive control for TLR3-independent cytokine production. 
Supernatants were collected 24h after stimulation and IL-6 ELISA was performed. (A-B) Mean values from 
two independent experiments with biological duplicates. Error bars represent SEM. (C-E) Mean values from 
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We report here the first case of human RIPK3 deficiency. This study provides experimental 
evidence of a causal relationship of a human RIPK3 genotype and a recessive phenotype of 
herpes simplex encephalitis.  
 
The mutant alleles carried by the patient are rare in the general population and predicted to be 
deleterious in silico. Our results on plasmid overexpression of the mutant constructs showed that 
the variants are indeed deleterious. At the expression level, both mutants codify aberrant proteins 
of a smaller molecular size, with P493fs9* showing lower levels of expression upon 
retrotransduction. At the functional level, the R422* mutant showed a lack of activity in all the 
assays tested. These results are consistent with the literature, as R422*, but not P493fs9*,  lacks 
the RHIM domain, which is required for the binding of upstream proteins (through RHIM-RHIM 
interactions) and consequently, ligand-dependent activation of RIPK3 through both auto- and 
transphosphorylation. We also confirmed that autosomal recessive RIPK3 deficiency at the 
population level is compatible with the incidence of the disease, as none of the common variants 
found in public databases seem to affect the expression or the function of RIPK3.  
 
RIPK3 protein expression was abolished in the patient in all the cell types tested. Probably due 
to the combinatory loss of R422* mRNA and P493fs9* protein. As such, RIPK3 signaling was 
impaired in the patient SV40-fibroblasts in both a TNFR1- and TLR3-dependent manner. These 
phenotypes can be rescued by RIPK3 overexpression, proving that the proband is indeed RIPK3-
deficient. Remarkably, we also showed for the first time that other patients with mutations in the 
TLR3 pathway (TLR3, TRIF, and UNC-93B) share an impaired RIPK3-mediated signaling, but in 
contrast to what we observed in our proband, this phenotype is only observed upon TLR3 
stimulation but not TNFR1 stimulation. These results combined, highlight the TLR3-RIPK3 axis 
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as the only pathway that is impaired in all these patients. Interestingly, TBK1+/- fibroblasts from 
a previously described HSE patient are able to signal through RIPK3 in a TLR3-dependent 
manner. Autosomal dominant TBK1 deficiency was described in two HSE patients and was 
originally thought to underlie this condition because of its involvement in the TLR3-IFN axis. 
However, a recent study using cells from these patients has shown that TBK1  is needed for early 
autophagy upon HSV-1 infection, which contrasts with other molecules of the TLR3 pathway such 
as TRIF, which was used in that study as a control (Ahmad et al., 2018).  
 
These new studies challenge the idea that mutations in the TLR3 pathway underlie HSE due to 
an impaired production of interferons. Our new model proposes that both IFNs and TLR3-RIPK3 
signaling are non-redundant mechanisms in humans to control HSV-1 in the brain; however, it 
might not be the direct activation of interferons by TLR3 what makes them essential  
(Figure 14). That would explain why TBK1+/- cells from HSE patients show a pattern of cellular 
phenotypes that differ from those observed in the rest of the patients. 
 
This shift in the paradigm that used to explain the molecular pathogenesis of HSE opens the door 
to new lines of research. RIPK3 crucial’s role in necroptosis suggests that necroptosis, similar to 
apoptosis, could be a non-redundant type of cell death in humans in natura. Necroptosis has been 
shown to restrict viral infection in several cell and mice models, and multiple viruses, including 
HSV-1, have been shown to both induce and target RIPK3 activity. However, to the date, there is 
no proof of principle that necroptosis is, as a biological mechanism, essential in humans. Although 
it is tempting to speculate whether necroptosis act as a non-redundant mechanism of antiviral 
immunity in the human forebrain, we remain cautious in our claims, as we do not have evidence 
that it is the dysregulation of the necroptotic signaling rather than another branch of the RIPK3 
cascade what is predisposing to HSE. Future studies in other patients (e.g., a patient with 
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mutations in MLKL or other RIPK3-associated molecules) may help elucidate the pathogenesis 
of the disease. 
 
Admittedly, with only one patient, we cannot draw firm conclusions about the spectrum of clinical 
manifestations that can be caused by other pathogens that were not encountered by our proband 
(such as CMV, ZIKV, or WNV). However, the report of this patient has tremendous medical 
implications. Although mice models of Ripk3 deficiency leading to viral encephalitis have been 
described (Daniels et al., 2017; Daniels et al., 2019), this experiment of nature provides the first 
evidence that human RIPK3 is protective from viral encephalitis in vivo. Recent studies have 
suggested the use of RIPK3 inhibitors for the treatment of ischemia-reperfusion injury or heart 
failure (Zhang et al., 2016). Our findings suggest that caution is required when considering this 
approach for disease treatment.  
 
Lastly, it is still unclear whether the mutations in RIPK3 are also responsible for the episode of 
post-herpetic autoimmune encephalitis. Some groups have connected RIPK3 to the NMDA 
receptor through the phosphorylation of CaMKII by RIPK3 (Wang et al., 2014; Bayer et al., 2001; 
Zhang et al., 2016), which in turn, phosphorylates one of the subunits of this receptor, regulating 
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